Erik C. Emerson - 16 May 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role
Chief Executive Officer, Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Issuer symbol
APUS
Transactions as of
16 May 2025
Transactions value $
$0
Form type
4
Filing time
20 May 2025, 16:56:19 UTC
Previous filing
08 May 2025
Next filing
17 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Emerson Erik C. Chief Executive Officer, Director C/O APIMEDS PHARMACEUTICALS US, INC., 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 20 May 2025 0001710496

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APUS Common Stock, par value $0.01 per share Award $0 +750K $0.00 750K 16 May 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APUS Stock option (right to buy) Award $0 +347K $0.00 347K 16 May 2025 Common Stock, par value $0.01 per share 347K $1.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Forty percent (40%) of the options vested immediately upon grant, and the remainder will vest in three equal annual installments beginning on 05/16/2026. The reporting person has agreed not to sell any shares underlying the options, even if exercised, for a period of three years from the date of grant.